Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different-dose remimazolam sedation during percutaneous kyphoplasty
ChiCTR2400092178Phase 4Not yet recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in compression fracture (VCF) (2 arms), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoints: VAS pain score and Ramsay sedation score. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
compression fracture (VCF)
Beyond the preview
Go deeper on ChiCTR2400092178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092178.